Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 72,440,928
  • Shares Outstanding, K 109,325
  • Annual Sales, $ 14,202 M
  • Annual Income, $ 4,413 M
  • EBIT $ 3,991 M
  • EBITDA $ 4,474 M
  • 60-Month Beta 0.27
  • Price/Sales 5.18
  • Price/Cash Flow 14.71
  • Price/Book 2.50

Options Overview Details

View History
  • Implied Volatility 33.71% ( -0.04%)
  • Historical Volatility 32.44%
  • IV Percentile 73%
  • IV Rank 60.37%
  • IV High 44.40% on 01/10/25
  • IV Low 17.43% on 06/12/24
  • Put/Call Vol Ratio 1.48
  • Today's Volume 2,280
  • Volume Avg (30-Day) 1,322
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 39,276
  • Open Int (30-Day) 35,827

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 7.29
  • Number of Estimates 6
  • High Estimate 9.01
  • Low Estimate 5.67
  • Prior Year 7.97
  • Growth Rate Est. (year over year) -8.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
651.06 +1.14%
on 03/21/25
748.29 -12.00%
on 03/10/25
-41.85 (-5.98%)
since 02/21/25
3-Month
642.00 +2.57%
on 02/04/25
748.29 -12.00%
on 03/10/25
-43.37 (-6.18%)
since 12/20/24
52-Week
642.00 +2.57%
on 02/04/25
1,211.20 -45.63%
on 08/27/24
-309.53 (-31.98%)
since 03/21/24

Most Recent Stories

More News
3 Reasons to Sell REGN and 1 Stock to Buy Instead

3 Reasons to Sell REGN and 1 Stock to Buy Instead

COST : 909.26 (+1.55%)
REGN : 658.48 (-0.62%)
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201.DR-0201 is...

NVS : 112.13 (-0.95%)
REGN : 658.48 (-0.62%)
PFE : 26.28 (+0.34%)
SNY : 56.90 (-1.54%)
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

NTRA : 151.15 (+1.02%)
EXAS : 45.62 (+3.03%)
INCY : 61.92 (+2.21%)
REGN : 658.48 (-0.62%)
2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off

2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off

ORLY : 1,339.09 (-0.30%)
REGN : 658.48 (-0.62%)
HSY : 167.18 (+1.65%)
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic...

ALNY : 283.34 (+11.75%)
NVS : 112.13 (-0.95%)
REGN : 658.48 (-0.62%)
RHHBY : 43.7000 (+0.64%)
3 Stocks With Ironclad Balance Sheets for Long-Term Stability

Check out these three stocks with balance sheets that have a case for being among the strongest in the entire stock market.

NVDA : 117.70 (-0.70%)
ANET : 83.13 (+0.19%)
VRTX : 503.20 (-1.37%)
REGN : 658.48 (-0.62%)
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

REGN : 658.48 (-0.62%)
Stock Index Futures Mixed After Yesterday’s Selloff, U.S. JOLTs Report in Focus

March S&P 500 E-Mini futures (ESH25) are down -0.04%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.54% this morning, pointing to a higher open on Wall Street after yesterday’s dramatic selloff,...

MSTR : 304.00 (+0.64%)
NVDA : 117.70 (-0.70%)
ASAN : 14.45 (+3.21%)
TSLA : 248.71 (+5.27%)
MTN : 160.67 (+0.11%)
NQH25 : 19,450.81s (-1.16%)
ORCL : 152.23 (-0.32%)
RKT : 14.11 (-1.60%)
REGN : 658.48 (-0.62%)
ESH25 : 5,617.80s (-0.79%)
DAL : 46.77 (-0.38%)
RDC.D.DX : 127.250 (-1.51%)
Stocks Fall on Growth Fears and Tech Stock Plunge

The S&P 500 Index ($SPX ) (SPY ) Monday closed down -2.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -2.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -3.81%. March E-mini...

MSTR : 304.00 (+0.64%)
GOOGL : 163.99 (+0.73%)
AAPL : 218.27 (+1.95%)
TAP : 58.89 (-0.17%)
HRL : 29.98 (+1.01%)
ADI : 204.40 (-0.73%)
ADM : 46.10 (-0.90%)
COIN : 189.86 (-0.27%)
TSLA : 248.71 (+5.27%)
CTSH : 76.42 (-1.02%)
^BTCUSD : 84,444.05 (+0.29%)
CME : 263.35 (-1.20%)
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies

Amgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET program that is evaluating the investigational anti-OX40 therapy rocatinlimab...

REGN : 658.48 (-0.62%)
AMGN : 316.04 (+0.32%)
SNY : 56.90 (-1.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 672.57
2nd Resistance Point 666.79
1st Resistance Point 662.63
Last Price 658.48
1st Support Level 652.69
2nd Support Level 646.91
3rd Support Level 642.75

See More

52-Week High 1,211.20
Fibonacci 61.8% 993.77
Fibonacci 50% 926.60
Fibonacci 38.2% 859.43
Last Price 658.48
52-Week Low 642.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar